Syndax Pharmaceuticals Inc at Cowen Oncology Innovation Summit: Insights for ASCO & EHA (Virtual) Transcript
Good afternoon and welcome once again to Cowen and Company's Third Annual Oncology Innovation Summit. I'm Phil Nadeau, one of the biotech analysts here at Cowen. And it's my pleasure to moderate a fireside discussion with Syndax Pharmaceuticals. We have with us today Michael Metzger, the Chief Executive Officer; and Anjali Ganguli, the Chief Business Officer.
And with that, we'll dive right into questions.
Questions & Answers
Most investor focus is on revumenib or SNDX-5613. Michael, could you give a brief summary of the efficacy data that were presented at ASH 2021 from AUGMENT-101 for those who are less familiar?
Sure. Pleasure to be here today. Phil. Thanks for having us and happy to summarize the data for you. So at ASH last December, we shared data from the Phase 1 portion of AUGMENT-101 testing revumenib, which is our menin inhibitor
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
